Nanobiotix Stock
Your prediction
Nanobiotix Stock
The Nanobiotix stock is trending slightly upwards today, with an increase of €0.015 (0.280%) compared to yesterday's price.
So far the community has only identified positive things for Nanobiotix stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Nanobiotix in the next few years
Pros
?
B****
?
S********** s********
?
M***** P*******
Cons
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Nanobiotix vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Nanobiotix | 0.280% | 4.399% | -4.643% | 217.479% | -16.822% | -60.356% | -53.403% |
| Valneva SE | -2.340% | -2.718% | -3.361% | -20.164% | -26.442% | -70.246% | 3.787% |
| Transgene S.A. | 1.430% | -9.246% | 17.279% | -28.874% | -4.776% | -51.849% | -55.848% |
| Quantum Genomics S.A. | 4.090% | 17.000% | 26.078% | -5.645% | 32.955% | -97.079% | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-05-11
Upon first glance, the financials of Nanobiotix, a company from the Biotechnology & Medical Research industry, seem to be facing a challenging financial situation. The company has continuously reported net losses and has a negative stockholder's equity as of the end of 2022. However, it is essential to dive deeper into the company's financial statements to better understand the underlying factors contributing to its current position.
Pros
Strong liquidity position: Nanobiotix's cash and short-term investments stood at €41,388,000 at the end of 2022, indicating a solid liquidity position to continue funding its research and development activities.